Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1FED 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1Depressive Disorder 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Selective Serotonin Reuptake Inhibitors × Clear all
NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

Completed
50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡